ALLEGAN – Perrigo Company Monday announced that it has received final approval
from the U.S. Food and Drug Administration for its Abbreviated New Drug
Application for over-the-counter Ibuprofen and Diphenhydramine
Citrate Tablets, 200/38 mg. Perrigo is expecting to begin product shipments
to retailers during the first quarter of calendar year 2009.
The product will be marketed under store brand labels and is comparable
to Wyeth Consumer Healthcare’s Advil(R) PM tablets, 200/38 mg, indicated as
a pain reliever (NSAID)/nighttime sleep-aid. Estimated brand sales for the
product for the last 12 months ending September 28, 2008 were $70 million.
�??We are obviously
delighted by this latest approval, which is another example of Perrigo’s
continuing investments to make quality healthcare more affordable to
American consumers,�?� said Perrigo Chairman and CEO Joseph Papa.
�??Investments like this one help save OTC healthcare
consumers approximately $1 billion annually when compared to the higher
priced national brands.�?�
Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes OTC and prescription pharmaceuticals,
nutritional products, active pharmaceutical ingredients (API) and consumer
products. The Company is the world’s largest manufacturer of OTC
pharmaceutical products for the store brand market. The Company’s primary
markets and locations of manufacturing facilities are the United States,
Israel, Mexico and the United Kingdom.
For more information, click on Perrigo.Com
a>>
